These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
199 related articles for article (PubMed ID: 35980831)
21. Androgens modify therapeutic response to cabazitaxel in models of advanced prostate cancer. Begemann D; Wang Y; Yang W; Kyprianou N Prostate; 2020 Sep; 80(12):926-937. PubMed ID: 32542812 [TBL] [Abstract][Full Text] [Related]
22. Metabolomic effects of androgen deprivation therapy treatment for prostate cancer. Chi JT; Lin PH; Tolstikov V; Oyekunle T; Chen EY; Bussberg V; Greenwood B; Sarangarajan R; Narain NR; Kiebish MA; Freedland SJ Cancer Med; 2020 Jun; 9(11):3691-3702. PubMed ID: 32232974 [TBL] [Abstract][Full Text] [Related]
23. Enhanced radiosensitization of enzalutamide via schedule dependent administration to androgen-sensitive prostate cancer cells. Ghashghaei M; Niazi TM; Heravi M; Bekerat H; Trifiro M; Paliouras M; Muanza T Prostate; 2018 Jan; 78(1):64-75. PubMed ID: 29134684 [TBL] [Abstract][Full Text] [Related]
24. Androgen deprivation therapy influences the uptake of 11C-choline in patients with recurrent prostate cancer: the preliminary results of a sequential PET/CT study. Fuccio C; Schiavina R; Castellucci P; Rubello D; Martorana G; Celli M; Malizia C; Profitos MB; Marzola MC; Pettinato V; Fanti S Eur J Nucl Med Mol Imaging; 2011 Nov; 38(11):1985-9. PubMed ID: 21732105 [TBL] [Abstract][Full Text] [Related]
25. Intermittent androgen deprivation in prostate cancer patients: factors predictive of prolonged time off therapy. Strum SB; Scholz MC; McDermed JE Oncologist; 2000; 5(1):45-52. PubMed ID: 10706649 [TBL] [Abstract][Full Text] [Related]
26. RGS2 is prognostic for development of castration resistance and cancer-specific survival in castration-resistant prostate cancer. Linder A; Larsson K; Welén K; Damber JE Prostate; 2020 Aug; 80(11):799-810. PubMed ID: 32449815 [TBL] [Abstract][Full Text] [Related]
27. Androgen deprivation‑induced OPHN1 amplification promotes castration‑resistant prostate cancer. Liu J; Zhang Y; Li S; Sun F; Wang G; Wei D; Yang T; Gu S Oncol Rep; 2022 Jan; 47(1):. PubMed ID: 34738630 [TBL] [Abstract][Full Text] [Related]
28. Statin Use at the Time of Initiation of Androgen Deprivation Therapy and Time to Progression in Patients With Hormone-Sensitive Prostate Cancer. Harshman LC; Wang X; Nakabayashi M; Xie W; Valenca L; Werner L; Yu Y; Kantoff AM; Sweeney CJ; Mucci LA; Pomerantz M; Lee GS; Kantoff PW JAMA Oncol; 2015 Jul; 1(4):495-504. PubMed ID: 26181260 [TBL] [Abstract][Full Text] [Related]
29. Bipolar Androgen Therapy for Men With Androgen Ablation Naïve Prostate Cancer: Results From the Phase II BATMAN Study. Schweizer MT; Wang H; Luber B; Nadal R; Spitz A; Rosen DM; Cao H; Antonarakis ES; Eisenberger MA; Carducci MA; Paller C; Denmeade SR Prostate; 2016 Sep; 76(13):1218-26. PubMed ID: 27338150 [TBL] [Abstract][Full Text] [Related]
30. Inherited variation in the androgen pathway is associated with the efficacy of androgen-deprivation therapy in men with prostate cancer. Ross RW; Oh WK; Xie W; Pomerantz M; Nakabayashi M; Sartor O; Taplin ME; Regan MM; Kantoff PW; Freedman M J Clin Oncol; 2008 Feb; 26(6):842-7. PubMed ID: 18281655 [TBL] [Abstract][Full Text] [Related]
35. Androgen deprivation therapy in prostate cancer and metabolic risk for atherosclerosis. Shahani S; Braga-Basaria M; Basaria S J Clin Endocrinol Metab; 2008 Jun; 93(6):2042-9. PubMed ID: 18349064 [TBL] [Abstract][Full Text] [Related]
36. Castration-resistant prostate cancer: a strategy to enhance response to androgen deprivation. Stanevsky Y; Tsivian A; Tsivian M Asian J Androl; 2013 Nov; 15(6):709-10. PubMed ID: 23893155 [TBL] [Abstract][Full Text] [Related]
37. Obesity is associated with castration-resistant disease and metastasis in men treated with androgen deprivation therapy after radical prostatectomy: results from the SEARCH database. Keto CJ; Aronson WJ; Terris MK; Presti JC; Kane CJ; Amling CL; Freedland SJ BJU Int; 2012 Aug; 110(4):492-8. PubMed ID: 22094083 [TBL] [Abstract][Full Text] [Related]
38. Androgen Receptor Signaling Inhibitors in Addition to Docetaxel with Androgen Deprivation Therapy for Metastatic Hormone-sensitive Prostate Cancer: A Systematic Review and Meta-analysis. Yanagisawa T; Rajwa P; Thibault C; Gandaglia G; Mori K; Kawada T; Fukuokaya W; Shim SR; Mostafaei H; Motlagh RS; Quhal F; Laukhtina E; Pallauf M; Pradere B; Kimura T; Egawa S; Shariat SF Eur Urol; 2022 Dec; 82(6):584-598. PubMed ID: 35995644 [TBL] [Abstract][Full Text] [Related]
39. N-cadherin increases after androgen deprivation and is associated with metastasis in prostate cancer. Jennbacken K; Tesan T; Wang W; Gustavsson H; Damber JE; Welén K Endocr Relat Cancer; 2010 Jun; 17(2):469-79. PubMed ID: 20233707 [TBL] [Abstract][Full Text] [Related]
40. Persistence of senescent prostate cancer cells following prolonged neoadjuvant androgen deprivation therapy. Blute ML; Damaschke N; Wagner J; Yang B; Gleave M; Fazli L; Shi F; Abel EJ; Downs TM; Huang W; Jarrard DF PLoS One; 2017; 12(2):e0172048. PubMed ID: 28234906 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]